The BM-MSCs treatment group exhibited markedly elevated expression of VEGFA and its cognate receptor VEGFR2 at both transcriptional and translational levels when compared to the DVT group, concomitant with a substantial decrease in the anti-angiogenic mediator sFlt1. Here, VEGFA is linked to deep vein thrombosis.